AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04731558 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No intervention
Description: No preoperative thromboprophylaxis.
Study NCT06521333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol-Based gel
Description: The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
Study NCT06521333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel 0.2%
Description: The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
Study NCT06521333 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stent
Description: The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
Study NCT05173753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novel self-adhesive hybrid composite(Surefil one)
Description: Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
Study NCT06272396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart watch
Description: ECG 1D/6D
Study NCT06462599 — intervention group
Intervention type: GENETIC
Intervention: Gene polymorphism from blood samples
Description: Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation
Study NCT04948359 — intervention group
Intervention type: OTHER
Intervention: Group I (The patients intubated with cuffed ETT of ID number 4.5)
Description: Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
Study NCT04948359 — intervention group
Intervention type: OTHER
Intervention: Group II (The patients intubated with cuffed ETT of ID number 5.0)
Description: Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
Study NCT04948359 — intervention group
Intervention type: OTHER
Intervention: Group III ( The patients intubated with cuffed ETT of ID number 5.5)
Description: Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
Study NCT06492525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 225 mg oral dose on day 1 in period 1 and on day 18 in period 2
Study NCT06492525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg QD from day 9 to day 22 in period 2
Study NCT06492525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg QD from day 9 to day 19 in period 2
Study NCT06492525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 100 mg oral dose on day 1 in period 1 and on day 12 in period 2
Study NCT04968275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS
Description: CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
Study NCT05438303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
Study NCT05438303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
Study NCT05438303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
Study NCT05438303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
Study NCT05438303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
Study NCT04844398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clown visits by RED NOSES Clowndoctors Austria
Description: Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
Study NCT05271877 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Diagnostic/operative laparoscopic procedure
Study NCT03705338 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalography
Description: Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
Study NCT03705338 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
Study NCT05593978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Medicine
Description: The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
Study NCT05593978 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
Study NCT05624970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training , tobacco cessation and nutritional advices
Description: 1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
Study NCT05624970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco cessation and nutritional advices
Description: Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
Study NCT05796934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moments that Matter (MTM) Program
Description: MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers).
Study NCT05744674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 228mg/342mg/456mg
Study NCT05744674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride Injection
Description: Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
Study NCT05198596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05198596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT05043662 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UroCAD assay, CTU examination and urine cytology
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
Study NCT05235269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: I124-AT01 only
Description: Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Study NCT05571332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 MG Oral Tablet
Description: p-ATG and CsA in combination with Avatrombopag to treat
Study NCT05488041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performing anorectal manometry
Description: Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, ... AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165.
Study NCT05488041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Performing anorectal manometry
Description: Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, ... AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165.
Study NCT06147388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colposcopy
Description: No surgery, observation
Study NCT05589857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPAD
Description: Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
Study NCT05589857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
Study NCT05403424 — intervention group
Intervention type: OTHER
Intervention: Evaluation of pain
Description: The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
Study NCT05403424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Application of pelvic girdle diagnostic tests
Description: Pelvic girdle pain diagnostic tests will be applied.
Study NCT05403424 — intervention group
Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia
Description: The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
Study NCT05403424 — intervention group
Intervention type: OTHER
Intervention: Evaluation of activity limitation
Description: Pelvic Girdle Questionnaire will be filled
Study NCT06655025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion during open heart surgery
Study NCT06655025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion during open heart surgery
Study NCT06655038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advocacy coalition
Description: * set up a task force composed of school stakeholders (students, teachers, educators, principle,...). These stakeholders will meet 4 times a year to improve the implementation and enforcement of TFSP through rules that are accepted, adopted and to which all school actors adhere.~* share of good practices in implementation with the other schools of the intervention arm through a sharing platform and two annual meetings.~* support to reffer nicotine-dependant students and staff members to smoking cessation programs.~* support in the implementation of TFSP and in getting all school actors on board, by the research team, but also by local health promotion partners.
Study NCT06655038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback on the basis of the audit and the surveys
Study NCT06655038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Description: Feedback on the basis of the audit and the surveys
Study NCT06595875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: m-tapa block
Description: Patients in Group M were placed in the supine position. After skin antisepsis with 5% povidone-iodine, a sterile drape was placed. The high-frequency (8-13 MHz) linear ultrasound (USG) probe was covered with a sterile sheath, and the transversus abdominis, internal oblique, and external oblique muscles were identified at the 10th costal margin in the sagittal plane at the costochondral angle. The probe was angled sagittally to visualize the costochondral angle at the edge of the 10th rib and to display the posterior surface of the rib cartilage in the midline. Using an in-plane technique, a 22-gauge, 100-millimeter (mm) Stimuplex A peripheral nerve block needle was advanced cranially, and the needle tip was directed towards the posterior surface of the 10th costal cartilage. After negative aspiration, 20 mL of 0.25% bupivacaine was injected under the lower surface of the costal cartilage. The same procedure was repeated on the opposite side.
Study NCT04509726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV-specific TCR-T cell with cytokine auto-secreting element
Description: Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
Study NCT04842812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
Description: TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
Study NCT05053646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meniscal repair
Description: The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
Study NCT05053646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal repair
Description: The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
Study NCT05053646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Marrow venting procedure
Description: After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
Study NCT06009211 — intervention group
Intervention type: OTHER
Intervention: QueaseEase
Description: Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
Study NCT05368012 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MIDCAB
Description: Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
Study NCT06523361 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: H'ability
Description: H'ability is introduced depending the randomization result, during the baseline (before session 4, 5, 6 or 7 with occupational therapist
Study NCT06522100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Methylprednisolone
Description: Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
Study NCT06522100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Prednisone
Description: After intravenous administration of Methylprednisolone patients will take by oral Prednisone 1mg/kg per day once a day (with a maximum dose of 90 mg per day for patients weighing > 90kg) for 1 month, followed with a progressive decrease of 10 mg Prednisone every 15 days until a dose of 10mg per day during 15 days (= stop).
Study NCT06522100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perfusion of placebo
Description: Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.